ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Many Medications: Understanding the Biologic Management of Psoriasis

Jason Liebowitz, MD, FACR  |  June 15, 2023

ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.

FDA Issues Updated Prescribing Information for Opioids & Over-the-Counter Naloxone

Michele B. Kaufman, PharmD, BCGP  |  June 13, 2023

New prescribing guidance has been issued by the FDA for immediate-release and extended-release/long-acting opioids for pain management. The agency also announced multiple label updates, which include changes to the Boxed Warnings.

Community Practice Council Holds First Meeting

Joseph Cantrell, JD  |  June 6, 2023

The April 29 meeting included 13 CPC members, representatives from the ACR Board of Directors and the chairs of the ACR Committee on Rheumatologic Care and its Insurance Subcommittee. The group is part of an expanded effort to ensure the ACR is meeting the needs of rheumatologists in independent practice.

After Pushback, Cigna Delays Modifier 25 Policy Changes

From the College  |  June 2, 2023

After significant pushback from the AMA, ACR and other medical societies, Cigna has delayed implementation of changes to its modifier 25 reimbursement policy, originally scheduled to take effect May 25.

Thick Skin & Solid Research: Necessary Ingredients for Publishing Success

Vanessa Caceres  |  June 1, 2023

Scientific publishing requires a commitment to clear writing, concise narratives and a willingness to accept feedback. Daniel Solomon, MD, editor-in-chief of Arthritis & Rheumatology, provides insights into his experiences.

Talking to Patients About Medicare Choices: Q&A with the Arthritis Foundation’s Nick Turkas, MS

Carina Stanton  |  May 31, 2023

Access to care is critical for treating arthritis and other chronic rheumatic conditions. That’s why choosing the best Medicare plan fit is such an important decision. Use these tips from the Arthritis Foundation’s Nick Turkas, MS, to help your patients make their best choice for insurance coverage.

RA Disease Activity & Alcohol Consumption Habits

Arthritis & Rheumatology  |  May 30, 2023

Past studies have suggested that patients with rheumatoid arthritis (RA) who consume a moderate amount of alcohol may experience lower disease activity and higher quality of life than non-drinkers. In this study, Alfredsson, et al. confirmed earlier studies’ claims that alcohol consumption reduces disease activity in a dose-dependent manner, and also indicated that patients who stopped drinking post-baseline experienced worsened disease activity, more pain and a lower quality of life.

ACR to Lead Resolutions at June AMA House of Delegates Meeting

From the College  |  May 23, 2023

The ACR will co-lead with the American Society of Clinical Oncology a resolution on in-office dispensing of specialty drugs and will lead 10 other specialty societies to advance a resolution on the proposed NIH Public Access Plan and equitable access to quality clinical research.

Charting a New Course Post-PHE

From the College  |  May 23, 2023

The public health emergency (PHE), in place since 2020, officially expired at midnight on May 11. The PHE declaration allowed significant flexibility in the healthcare system. The end of the PHE impacts several policies, including changes in Medicare and Medicaid policies. What do these changes mean for providers?

Slow but Steady: 2023 State Legislative Progress

Joseph Cantrell, JD  |  May 23, 2023

This legislative season has seen key pharmacy benefit manager reforms but slow movement on other issues, such as copay accumulators and utilization management. The ACR is also monitoring emerging topics, such as biomarker testing and post-public health emergency telehealth reforms.

  • « Previous Page
  • 1
  • …
  • 46
  • 47
  • 48
  • 49
  • 50
  • …
  • 330
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences